Ensuring GLP compliance in labs

August 22, 2025

Introduction to Good Laboratory Practices (GLP)

Good Laboratory Practices (GLP) are fundamental to ensuring the quality and integrity of non-clinical studies, particularly those that underpin regulatory submissions. Established out of necessity in the 1970s due to scientific misconduct, GLP provides a comprehensive framework that laboratories must follow to guarantee reliable and reproducible data. This article explores various facets of GLP, from its principles and historical significance to compliance monitoring, thereby elucidating its pivotal role in scientific research and public health safety.

Understanding Good Laboratory Practices (GLP)

What are Good Laboratory Practices (GLP)?

Good Laboratory Practices (GLP) are a set of principles designed to ensure the quality and integrity of nonclinical laboratory studies that support regulatory applications, particularly in drug development. Established due to concerns over the reliability of safety data in the early 1970s, GLP regulations are codified in 21 CFR Part 58 and are enforced by organizations such as the FDA .

GLP covers aspects like:

  • Planning : Outlining the study requirements.
  • Performance : Conducting experiments under controlled conditions.
  • Monitoring : Ensuring adherence to established protocols.
  • Recording : Documenting all procedures and findings accurately.
  • Reporting : Creating traceable and auditable documents.
  • Archiving : Retaining data and materials for future reference.

Compliance with GLP is essential for studies pertaining to pharmaceuticals, pesticides, and other chemical substances, while it does not apply to human clinical studies or basic research.

Importance in regulatory applications

Compliance with GLP enhances public health and safety by providing accurate data to regulatory agencies like the FDA and EMA . These agencies require that laboratories adhere to GLP standards to ensure the safety and efficacy assessments of new products. The implications of failing to comply with these standards can include significant delays in product approvals or even rejection of studies.

Scope of GLP

GLP regulations encompass various sectors, including pharmaceuticals, pesticides, and chemicals. They ensure not just the accuracy of the data generated but also the promotion of best practices across laboratories globally. The OECD Principles of GLP reinforce these standards, making GLP a critical framework ensuring the safety and welfare of humans and animals involved in research.

Why GLP is Critical to Scientific Research

Why is Good Laboratory Practice (GLP) important in scientific research?

Good Laboratory Practice (GLP) is essential in scientific research as it promotes consistency and reliability in laboratory results, which is crucial for drawing valid conclusions. By adhering to standardized protocols, GLP minimizes variability and errors in experiments, enhancing the overall quality of research data.

Moreover, strict documentation and record-keeping requirements help maintain traceability and accountability, which are vital for regulatory compliance and audits. This structured approach fosters transparency and aids in reproducibility of findings by other researchers, thus furthering scientific knowledge.

The role of GLP extends beyond just ensuring quality; it plays a significant part in regulatory compliance. Regulatory agencies like the FDA and EMA mandate GLP adherence for approving new products, reinforcing the importance of rigorous testing protocols.

In summary, GLP contributes to public confidence in research outcomes, ensuring that scientific innovations are built on a solid foundation of dependable data. This adherence ultimately promotes safety and efficacy in the development of new drugs, chemicals, and other products critical to human health.

Core GLP Principles and Guidelines

What are the main principles and guidelines of Good Laboratory Practices (GLP)?

The principles and guidelines of Good Laboratory Practices (GLP) are essential in regulating the conduct of non-clinical laboratory studies. According to 21 CFR Part 58, GLP focuses on the organizational processes and conditions that ensure the quality and integrity of data collected during studies. The key components of GLP include:

  • Organization and Personnel : Clearly defined roles within the laboratory, including responsibilities of test facility management and quality assurance personnel.
  • Quality Assurance : A dedicated Quality Assurance Unit (QAU) must exist to conduct regular inspections and audits, maintaining protocol adherence and data integrity.
  • Facilities and Equipment : Laboratories must have suitable facilities, and all equipment must be appropriately calibrated and maintained to yield reliable results.
  • Documentation : Comprehensive and well-organized documentation is paramount, covering everything from study protocols to data collection methods. This ensures reproducibility and compliance during audits.

Regulatory frameworks and guidelines

GLP compliance is mandated by various regulatory agencies, most notably by the FDA and EPA in the U.S. and the EMA in Europe. The frameworks enforced by these regulatory bodies ensure adherence to GLP standards, which are crucial for studies pertaining to pharmaceuticals, pesticides, and other chemicals. Following well-defined GLP guidelines helps mitigate risks associated with testing products for safety and efficacy.

Role of SOPs

Standard Operating Procedures (SOPs) serve a critical role in GLP compliance. They provide detailed instructions for the conduct of experiments, ensuring that all processes are consistent and repeatable. SOPs help calibrate methods across various studies, facilitating accurate data logging and contributing greatly to overall data integrity and reliability. Regular training sessions on SOP adherence further instill a strong culture of compliance and safety within laboratory settings.

Monitoring and Ensuring Compliance with GLP

How does GLP compliance monitoring work?

GLP compliance monitoring is integral to maintaining the integrity of scientific data produced in laboratories. This structured process consists of regular inspections and audits of testing facilities. These inspections are carried out to ensure that laboratories adhere to the Good Laboratory Practice (GLP) principles, which comprise well-defined protocols regarding personnel qualifications, facility suitability, and documentation procedures.

National GLP Monitoring Authorities hold the responsibility of implementing specific procedures that tailor the compliance programs to their regulations. This includes establishing the frequency and scope of inspections and ensuring that organizations comply with both locally applicable GLP standards and international guidelines, such as those set forth by the OECD.

The process also emphasizes confidentiality, especially regarding commercially sensitive information discovered during inspections. This is crucial as it protects proprietary data while still enabling regulatory bodies to verify compliance. By adhering to the OECD Principles of Good Laboratory Practice, countries align their monitoring approaches, facilitating mutual acceptance of regulatory test data across borders.

In summary, GLP compliance monitoring serves as a safeguard for scientific integrity and the reliability of laboratory studies, ultimately contributing to public health and safety.

Strategies for Achieving GLP Compliance

What strategies can laboratories employ to ensure GLP compliance?

Laboratories can undertake several strategies to uphold GLP compliance effectively. A cornerstone of these strategies is establishing and communicating clear GLP expectations and guidelines to all personnel involved in research and testing processes. This includes creating a robust Chemical Hygiene Plan that details safety practices and necessary equipment for protecting employees from hazardous exposures.

Moreover, continuous training and monitoring of employees are paramount. Staff must be educated about the hazards associated with the chemicals they work with, including awareness of permissible exposure limits. This training should encompass the execution of GLP standards in daily operations.

Laboratory Infrastructure

Setting up designated areas for specific hazardous substances is crucial. These areas should be equipped with appropriate safety measures, thereby fostering a culture of safety where deviations from established procedures are swiftly addressed. Additionally, ensuring that the laboratory infrastructure meets GLP requirements is fundamental. This might involve regular maintenance and calibration of equipment, establishing a Quality Assurance Unit (QAU), and designing facilities conducive to GLP practices.

Staff Training Programs

Regular training sessions should focus not only on GLP practices but also on emerging regulations and technologies. Training programs can utilize simulations and real-world scenarios to enhance understanding. Integrating feedback from audits and inspections into training can also improve adherence to safety protocols.

Implementation of SOPs

Establishing Standard Operating Procedures (SOPs) is essential in achieving GLP compliance. SOPs must be detailed and accessible, ensuring all staff are trained on their importance and execution. Regular updates of these procedures to reflect changes in regulations or laboratory practices can help maintain integrity and compliance in data generation and reporting.

By creating a structured environment focused on safety and compliance, laboratories can not only fulfill regulatory requirements but also promote a culture of quality and integrity in research.

Consequences of GLP Non-Compliance

What are the consequences of non-compliance with GLP standards?

Non-compliance with GLP standards can lead to a multitude of severe repercussions that affect not just laboratories, but also public health and the financial stability of organizations involved in non-clinical studies.

Legal repercussions

Laboratories that fail to adhere to GLP regulations may face legal actions including hefty fines, inspections, and even potential criminal prosecutions. Regulatory bodies like the FDA and EPA closely monitor compliance, and violations can lead to serious legal consequences, forcing organizations to allocate significant resources to rectify non-compliance issues.

Impact on public health

The consequences extend to public health as well. The generation of unreliable data can lead to erroneous conclusions about product safety, resulting in unsafe medications, chemicals, or pesticides hitting the market. These compromised products can increase the risk of harmful side effects or even fatalities, ultimately leading to more product recalls and a crisis of consumer trust.

Financial implications

From a financial perspective, the ramifications are equally daunting. Laboratories may experience substantial financial losses due to high rates of rejected studies, which often necessitate costly repeat testing. Moreover, the damage to an institution’s reputation can hamper future business opportunities, as clients and partners become wary of associating with non-compliant facilities.

In summary, the stakes of GLP non-compliance are high, impacting legal standings, public safety, and financial health, thus emphasizing the importance of strict adherence to GLP standards.

Historical Context and Evolution of GLP

Origins of GLP

Good Laboratory Practices (GLP) emerged in the 1970s as a response to increasing concerns over scientific misconduct in laboratory settings. The infamous case involving IBT Laboratories highlighted the need for stringent quality assurance measures to ensure the integrity of laboratory data and protect public health. In 1978, the FDA introduced guidelines to establish GLP standards, aiming to prevent fraud and ensure that safety studies were conducted consistently and reliably.

Key Developments Over Time

Following the initial FDA guidelines, the OECD published its foundational GLP principles in 1981, which many countries adopted to harmonize laboratory practices. This shift led to a more structured approach toward data integrity and quality assurance in laboratories across various sectors, such as pharmaceuticals, chemicals, and environmental studies. Over the years, regulatory frameworks around GLP have evolved to include comprehensive documentation practices, personnel training requirements, and rigorous facility maintenance protocols, reflecting an increasing commitment to scientific rigor.

Globalization and Harmonization

As global trade expanded, the need for internationally recognized compliance standards led to a push for harmonized GLP practices. Regulatory bodies like the FDA and EMA have established overlapping frameworks to ensure that data from nonclinical studies meet rigorous quality and safety standards. This globalization of GLP helps facilitate the acceptance of laboratory studies worldwide, ensuring that the data supporting product safety assessments are reliable and robust.

Regulatory Framework and International Standards

Role of FDA, EPA, and OECD

The regulatory landscape for Good Laboratory Practice (GLP) is shaped primarily by three key organizations: the FDA , the EPA , and the OECD . The FDA governs GLP regulations for pharmaceuticals, ensuring compliance for nonclinical laboratory studies submitted for product registrations. The EPA oversees GLP compliance for studies involving pesticides and industrial chemicals. Both agencies enforce stringent protocols to safeguard data integrity and public health.

International Harmonization Efforts

Efforts towards international harmonization of GLP standards have led to the establishment of guidelines by organizations such as the OECD , which published foundational GLP principles in 1981. These efforts aim to standardize requirements across countries, fostering better cooperation in regulatory reviews and enhancing the acceptability of GLP-compliant studies globally. Regulatory bodies in various regions, including the EMA in Europe, align their guidelines with these standards to ensure consistency.

GLP in Different Industries

GLP compliance is integral not just in pharmaceuticals, but also across various industries including pesticides, cosmetics, and food additives. Each sector adapts GLP principles to suit specific research needs, ensuring that all non-clinical studies provide reliable and valid data for regulatory submissions. This broad applicability of GLP underscores its importance in maintaining quality assurances in safety assessments and data integrity for public health.

Technological Tools Supporting GLP Compliance

Software Solutions for Data Integrity

Technological advancements have led to the development of specialized software that supports Good Laboratory Practice (GLP) compliance. Tools like the LabLynx ELab LIMS offer features for securely storing Standard Operating Procedures (SOPs) and managing regulated documentation. These solutions facilitate time-stamped data entry, ensuring traceability and accountability across various testing stages.

Facilities and Equipment Management

Effective GLP compliance requires proper management of laboratory facilities and equipment. Regular calibration and maintenance schedules can be monitored using software tools, ensuring that all instruments are reliable and functions are well-documented. This practice not only supports compliance during inspections but also enhances the accuracy of experimental data.

Innovations in Compliance Tracking

Recent innovations in compliance tracking systems allow laboratories to automate routine auditing processes. Real-time data monitoring can detect potential discrepancies and facilitate prompt corrective actions. By leveraging these technological tools, laboratories can maintain GLP standards more efficiently, ultimately leading to higher data integrity and reliability in nonclinical studies.

Future Directions in GLP Practices

Emerging Trends

In the realm of Good Laboratory Practice (GLP), emerging trends indicate a growing emphasis on data integrity and transparency . Regulatory bodies are increasingly advocating for technologies that enhance data traceability, ensuring that all aspects of laboratory studies can be verified at any time.

Potential Changes in Regulations

As the industry evolves, we may observe changes in GLP regulations that integrate more robust frameworks addressing environmental sustainability and ethical considerations in research, particularly in animal testing. Regulatory agencies might also focus on harmonizing global GLP standards to facilitate international collaboration and approvals.

Impact of Technological Advancements

Technological advancements are poised to significantly impact GLP compliance. The use of automated systems for data collection and reporting can reduce human errors, while AI-driven analytics could enhance the effectiveness of quality assurance measures. These innovations will likely lead to improved operational efficiencies and cost reductions, benefiting laboratories striving for compliance.

Aspect Current Focus Future Directions
Data Integrity Manual documentation processes Automated, traceable data systems
Regulations National standards Global harmonization of GLP practices
Technological Integration Basic software tools Advanced AI and analytics in quality control

Conclusion: The Road Ahead for GLP in Laboratories

As laboratories continue to evolve in response to technological advancements and stricter regulatory requirements, adhering to Good Laboratory Practices remains crucial. Maintaining GLP compliance not only ensures the production of reliable and reproducible data but also aids in safeguarding public health and facilitating international collaboration. By embracing comprehensive GLP training, robust infrastructure, and cutting-edge compliance tools, laboratories can not only meet but exceed the stringent demands of GLP regulation, ultimately fostering innovation and trust in scientific research.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More